With a median follow - up of 14 months, patients assigned to combination treatment with cobimetinib and vemurafenib had a progression - free survival of 12.3 months compared with 7.2 months for those on
vemurafenib alone.
It included a total of 577 patients randomized to receive either encorafenib plus binimetinib (192 patients), encorafenib alone (194 patients), or
vemurafenib alone (191 patients).